Royal London Asset Management Ltd. Raises Holdings in Danaher Corporation $DHR

by · The Cerbat Gem

Royal London Asset Management Ltd. increased its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 209.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,007,284 shares of the conglomerate’s stock after buying an additional 681,996 shares during the period. Royal London Asset Management Ltd.’s holdings in Danaher were worth $191,867,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of DHR. BlackRock Inc. purchased a new stake in shares of Danaher during the second quarter valued at about $10,492,520,000. Norges Bank purchased a new stake in Danaher during the fourth quarter valued at approximately $2,177,106,000. Jupiter Topco LLC acquired a new stake in Danaher in the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP purchased a new position in Danaher in the second quarter worth $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in shares of Danaher during the second quarter worth $993,846,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $216.41 on Friday. The business has a fifty day moving average of $199.46 and a 200 day moving average of $192.52. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The firm has a market capitalization of $152.13 billion, a price-to-earnings ratio of 38.44, a price-to-earnings-growth ratio of 2.69 and a beta of 0.78.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 EPS. As a group, research analysts expect that Danaher Corporation will post 8.53 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on DHR shares. Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. HSBC decreased their price target on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Evercore reissued an “outperform” rating and issued a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Guggenheim dropped their price target on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, Piper Sandler initiated coverage on shares of Danaher in a research report on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $228.91.

Check Out Our Latest Research Report on Danaher

Danaher Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).